MJMarjia Johns

Marjia Johns

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marjia Johns has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Seasonal Variation in Skin Cancer Presentation in Primary Care Clinic in Parramatta, NSW

    by Marjia Johns, Yagiz Aksoy, Gilberto Moreno Bonilla

    Background: Seasonal variation in melanoma and keratinocyte cancer (KC) diagnoses has been noted in the literature, predominantly from northern hemisphere populations, with summer peaks most commonly noted. There is limited contemporary literature from Australian data. This is the first study to our knowledge to examine both melanoma and KC presentations in Australia, and the first to investigate this in a primary care setting. Methods: A retrospective study was performed based on histopathological data taken from a primary care clinic in Parramatta NSW between March 2016 and March 2025. Inclusion criteria were basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Multiple complementary analytical approaches were performed, including cosinor harmonic regression, negative binomial models, mixed‐effects models, time series decomposition, and Bayesian inference. Multiple sensitivity analyses were also performed to assess the robustness of the findings. Results: 9778 skin cancers were included over a nine‐year period, which included BCC; ( n = 5290; 54.1%), SCC; ( n = 4041; 41.3%), and melanoma ( n = 447; 4.6%). Seasonal differences were statistically significant; however, clinically negligible. Conversely, there was a demonstrated reduction in presentations at the onset of COVID‐19, with sustained reduction in presentations through to 2024. Discussion: No clinically significant seasonal variation in skin cancer presentations was found, in direct contrast with literature from the northern hemisphere. This may reflect Australia's milder climate and relatively high annual ultraviolet index, effective public health messaging, and the accessibility of primary care services. Deficits in presentations throughout the year appear operation‐dependent as opposed to biological seasonality. The significant and sustained impact of COVID‐19 on skin cancer presentation raises concerns regarding the ongoing impact of delayed diagnoses of skin cancer in the Australian population. Conclusion: No clinically significant seasonal variation in skin cancer presentation was found in a large primary care skin cancer cohort in metropolitan Sydney; however, COVID‐19 exerts a substantial and sustained impact. Vigilance regarding the long‐term consequences of pandemic‐related healthcare disruptions is warranted.

  • Frozen Section Mohs Micrographic Surgery for Dermatofibrosarcoma Protuberans—A Case Series of 38 Patients in NSW , Australia

    by Marjia Johns, Maya Deva, Gilberto Moreno Bonilla, Simon Lee, Duncan Graham Stanford, Saleem Loghdey

    Background: Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous tumour with a locally infiltrative growth pattern that has high rates of recurrence. Mohs micrographic surgery is recommended as the gold‐standard treatment over wide local excision (WLE) due to tissue‐sparing and reduced recurrence rates. No previous data on surgical outcomes following Mohs Micrographic Surgery (MMS) for DFSP have been reported in Australia to date. This study aims to review the outcomes of DFSP treated with frozen‐section MMS across three centres in New South Wales (NSW), Australia, and compare these outcomes with those in the current literature. Methods: A retrospective review of patients who underwent MMS for DFSP between 2010 and 2023 was performed. Patient demographics, histological findings, surgical treatment and follow‐up data were collected. Recurrence was assessed through electronic medical records, clinical assessments by a dermatologist or general practitioner, and patient self‐report. Results: In all, 38 cases of DFSP were included (27 female, 11 male; median age 39 years, range 16–64). The trunk was the most common site. Clinical margins and Mohs stages were recorded in 37 of 38 cases, with 73% of cases cleared with clinical margins of ≤ 20 mm. Clinical or self‐reported follow‐up was available for 28 of 38 patients (73.6%) over a mean of 51 months (range, 5–132 months). No local recurrences were identified during this period. Conclusion: This is the first Australian case series on MMS for DFSP. Our findings demonstrate no recurrences with follow‐up and demonstrate that MMS may achieve clearance with smaller clinical margins than WLE. These results support international guidelines recommending MMS as the gold‐standard treatment and highlight the need to improve access to MMS in Australia.

  • Primary Vulvovaginal Melanoma: A Fifteen‐Year Multidisciplinary Team Experience

    by Marjia Johns, Gilberto Moreno Bonilla, Florence Garty, Jeremy Hurren, Deidre McCormick, Dirk Brinkmann, Bronwyn R. Hughes

    Vulvovaginal melanoma is a rare malignancy with a poor prognosis and variable clinical presentation. In a 15‐year retrospective review, we identified 15 cases where wide local excision was the most common treatment. Serial digital photography was implemented to support early detection, monitoring and clinician education.

  • Intravascular Basal Cell Carcinoma During Mohs Surgery

    by Marjia Johns, Nicholas Stewart, Saleem Loghdey, Gilberto Moreno Bonilla

    Intravascular invasion of basal cell carcinoma is an exceedingly rare finding during Mohs' micrographic surgery. We present three cases and discuss its significance and management implications.

  • Comparison of Keratinocyte Cancer Tumour and Defect Sizes Treated by Mohs Micrographic Surgery: Sydney Versus Outside Metropolitan Sydney

    by Marjia Johns, Hannah Kunst, Vivian Tng, John Frew, Cindy Kok, Simon Lee, Gilberto Moreno Bonilla

    Background: Australia and New Zealand face the world's highest skin cancer rates, with non‐metropolitan regions bearing a greater burden. Mohs micrographic surgery (MMS) is the gold‐standard treatment for keratinocyte cancers (KCs) due to high cure rates and tissue‐sparing benefits. This study evaluates whether Outside Metropolitan Sydney (OMS) patients present with larger tumours and defects than Sydney Metropolitan Area (SMA) patients.Methods: This retrospective study examined MMS cases at The Skin Hospital in 2017. Patients were divided into Sydney Metropolitan Area (SMA) and Outside Metropolitan Sydney (OMS), with OMS sub‐grouped into Non‐Sydney Metropolitan (NSM) and Regional, Rural and Remote (RRR). Tumour and defect sizes were compared between OMS, SMA, and RRR and NSM, with additional exploratory analyses assessing surgical outcomes and tumour characteristics.Results: Of 2073 patients undergoing MMS, 1870 basal cell carcinomas and 203 squamous cell carcinomas were included. Tumours and defects were significantly larger in OMS patients (median tumour size: 0.8 cm2, defect size: 2.1 cm2) compared to SMA patients (median tumour size: 0.7 cm2, defect size: 1.8 cm2). No correlation was found between distance travelled and tumour or defect size. SMA patients also had greater flap and primary closures than OMS. Subgroup analysis of RRR and NSM showed no significant difference in tumour or defect sizes.Conclusions: Patients from OMS presented with larger KCs, suggesting barriers to earlier access to specialised care. This highlights geographic disparities in skin cancer management outside major cities in Australia in the context of MMS, emphasising the need for improved access and dermatological workforce distribution.